Department of Health Policy and Management and Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Health Econ. 2013 Oct;22(10):1272-81. doi: 10.1002/hec.2879. Epub 2012 Oct 19.
Interpreting the outcomes of cost utility analyses requires an appropriately defined threshold for costs per quality-adjusted life year (QALY). A common view is that the threshold should represent the (consumption) value a society attaches to a QALY. So far, individual valuations of personal health gains have mainly been studied rather than potentially relevant social values. In this study, we present the first direct empirical estimates of the willingness to pay for a QALY from a societal perspective. We used the contingent valuation approach, valuing QALYs under uncertainty and correcting for probability weighting. The estimates obtained in a representative sample of the Dutch population (n = 1004) range from €52,000 to €83,000, depending on the specification of the societal perspective. The scale sensitivity was weak, however.
解释成本效用分析的结果需要为每质量调整生命年（QALY）的成本定义一个适当的阈值。一种常见的观点认为，该阈值应代表（消费）社会赋予 QALY 的价值。到目前为止，个人对个人健康收益的评估主要是在研究，而不是潜在的相关社会价值。在这项研究中，我们首次从社会角度直接估计了支付意愿。我们使用了条件价值评估方法，在不确定的情况下对 QALY 进行了估值，并对概率加权进行了修正。在荷兰代表性人群样本（n=1004）中获得的估计值在 52,000 欧元至 83,000 欧元之间，具体取决于社会视角的具体说明。然而，规模敏感性较弱。
